Guselkumab Improves Symptoms and Disease Progression in Psoriatic Arthritis
Treatment with Guselkumab led to improved joint symptoms and reduced radiographic progression vs placebo in biologic-naïve adults with active PsA.
Guselkumab, a selective interleukin (IL)-23p19 inhibitor, significantly improves joint symptoms and prevents radiographic disease progression compared with placebo among biologic-naïve adults with active psoriatic arthritis (PsA), with a favorable safety profile.
- The APEX trial is an ongoing, multicenter, randomized, double-blind, placebo-controlled phase 3b study.
- Researchers enrolled biologic-naïve adults with active PsA (≥3 tender and swollen joints, C-reactive protein ≥0.
Guselkumab significantly improves joint symptoms and prevents radiographic disease progression.
Author summary: Guselkumab improves symptoms in PsA patients.